Ace Biopharm history, from its founding in 2004 to KRW 127.7 billion in revenue

Secured external investment (July 2026)

Expanded 2 CDMO business

initiated "License-in" business

Achieved KRW 127.7 billion in revenue (Approx. USD 100M)

Reached 232 cumulative DMF registrations (61 new approvals) and 5 finished drug marketing authorizations

Surpassed USD 3 million in overseas exports (Vitamin K2 and key ingredients to the US & Europe)

Obtained Kosher (Star-K) and Halal (IHCC) certifications

Certified as an Innovative Venture Business (Venture Investment Type)

Achieved KRW 121 billion (Approx. USD 91M) in revenue

Reached 177 cumulative DMF registrations (18 new approvals) and 2 marketing authorizations

Launched CDMO business division

Celebrated the 20th anniversary of company founding

Achieved KRW 108 billion (Approx. USD 81M) in annual revenue

Reached 159 cumulative DMF registrations (12 new approvals) and 11 drug marketing authorizations

Secured distribution partnership for Evonik pharmaceutical excipients

Registered formulation patent: "Oral tablet containing fenofibric acid and method for preparing the same" (Patent No. 10-2501636)

Achieved KRW 100 billion in revenue (Approx. USD 75 M)

Reached 147 cumulative DMF registrations (20 new approvals)

Acquired and relocated to the new corporate headquarters in Bangbae-dong (August 2022)

Commenced distribution of Seppic pharmaceutical excipients

Achieved KRW 86.3 billion (Approx. USD 65M) in annual revenue

Reached 127 cumulative DMF registrations (36 new approvals)

Rebranded corporate name from Dongjin Pharma Co., Ltd. to Ace Biopharm Co., Ltd.

Certified as a Family-Friendly Company and recognized as an Outstanding Company for Employment Stability

Pyeongtaek Plant opened (November 1, 2021) and ISO 22000 certified

Designated as a Global Small Giant Company

Launched Evonik’s EUDRAGIT® products

Achieved KRW 76.5 billion (Approx. USD 59M) in annual revenue

Registered 91 cumulative DMF products, including 11 newly registered products

Designated as a Hi-Seoul Brand Company and selected as a Youth-Friendly Small Giant Company

Selected as the lead organization for the Industrial Core Technology Development Project by the Ministry of Trade, Industry and Energy (MOTIE)

Selected as Export SME in the second half of 2020

Received the $1 Million Export Tower Award from the Korea International Trade Association (KITA)

Achieved KRW 71.3 billion (Approx. USD 56M) in annual revenue

Registered 80 cumulative DMF products, including 26 newly registered products

Merged with Ace Biotech Co., Ltd.

Established the Daejeon Bio R&D Center

Received the 2019 Win-Win Development Award of Korea

Achieved KRW 58.0 billion (Approx. USD 51M) in annual revenue

Registered 54 cumulative DMF products, including 16 newly registered products

Established the Corporate R&D Center (November 26, 2018) and obtained KGIP Laboratory Certification (December 13th, 2018)

Registered three patents and filed one patent application related to Vitamin K2 production

Achieved KRW 55 billion (Approx. USD 48M) in annual revenue

Registered 38 cumulative DMF products, including 8 newly registered products

Constructed a 430 m² logistics warehouse at the Hwaseong Logistics Center

Recognized as a Strong SME and a Technology-Driven Company

Achieved KRW 50 billion (Approx. USD 44M) in annual revenue

Acquired and relocated to a new corporate headquarters (September)

Designated as a Youth-Friendly SME

Achieved KRW 30.0 billion (Approx. USD 26.5 M) in annual revenue

Designated as MAIN-BIZ

Achieved KRW 20.0 billion (Approx. USD 18.2M) in annual revenue

Relocated the Logistics Center

Signed exclusive supply agreements for choline alfoscerate with Korea Biochem Pharm and Korea Prime Pharm

Established affiliate Ace Biotech Co., Ltd.

Achieved KRW 11.0 billion (approx. USD 10.0 million) in annual revenue

Signed exclusive supply agreements with more than 10 companies covering over 20 products

Established the Company with paid-in capital of KRW 200 million (Approx. USD 0.2M)